Betta Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Lieming Ding

Geschäftsführender

CN¥2.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	11.3yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Recent updates

We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings

Nov 04

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Sep 30

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 07

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

Jul 30

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Jul 05

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Apr 26

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Apr 23

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Apr 16

Geschäftsführer

Lieming Ding (61 yo)

11.3yrs

Amtszeit

CN¥2,900,800

Vergütung

Dr. Lieming Ding founded Betta Pharmaceuticals Co., Ltd.(also known as Zhejiang BetaPharma Co., Ltd) in 2002 and serves as its Chairman. Dr. Ding has been Chief Executive Officer and General Manager of Bet...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Lieming Ding	Founder	no data	CN¥2.90m	0.24% CN¥ 45.4m
Jianxun Fan	VP, CFO & Director	no data	CN¥1.46m	0.031% CN¥ 6.0m
Jiang Wan	Senior VP	5yrs	CN¥2.55m	0.025% CN¥ 4.8m
Jia Tong	Director	no data	CN¥1.46m	0.039% CN¥ 7.6m
Wei Wang	Independent Director	5yrs	CN¥120.00k	keine Daten
Cai Jiangnan	Independent Director	5yrs	CN¥120.00k	keine Daten
Yangnan Zhang	Chairman of the Supervisory Board & Senior Director of Project Declaration	5yrs	CN¥870.70k	keine Daten
Zhihua Yu	Director	5yrs	keine Daten	keine Daten
Tian Xu	Director	2.1yrs	keine Daten	keine Daten
Fei Wu	Supervisor	no data	CN¥860.20k	keine Daten
Jiajia Xiao	Independent Director	2.1yrs	CN¥120.00k	keine Daten
Rong Wang	Shareholder Supervisor	1.9yrs	keine Daten	keine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 300558Die Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).

Betta Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Recent updates

We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings

Consensus EPS estimates increase by 24%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 16%

Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 29% Share Price Bounce

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 33%

New minor risk - Share price stability

Consensus EPS estimates increase by 15%, revenue downgraded

Results: Betta Pharmaceuticals Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

New minor risk - Earnings quality

Second quarter 2024 earnings: EPS exceeds analyst expectations

Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares

These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Reasonably Well

Betta Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Dividend increased to CN¥0.17

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares as Cash Dividend (Tax Included) for the Year 2023, Payable on 06 June 2024

Consensus EPS estimates fall by 17%

Price target decreased by 9.5% to CN¥51.64

Betta Pharmaceuticals' (SZSE:300558) Earnings Are Weaker Than They Seem

Consensus EPS estimates increase by 20%, revenue downgraded

Earnings Miss: Betta Pharmaceuticals Co., Ltd. Missed EPS By 6.1% And Analysts Are Revising Their Forecasts

Price target increased by 12% to CN¥65.00

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, May 15, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

What Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Not Telling You

Betta Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 18%

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Consensus EPS estimates increase by 12%, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Betta Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Consensus EPS estimates fall by 13%

Price target decreased by 16% to CN¥57.04

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023

Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022

Price target increased by 13% to CN¥50.59

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Betta Pharmaceuticals Co., Ltd. Approves Board Elections

Insufficient new directors

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 11%

Price target decreased to CN¥57.39

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding

Investor sentiment improved over the past week

Betta Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Payable on 30 May 2022

High number of new and inexperienced directors

Betta Pharmaceuticals Co., Ltd., Annual General Meeting, Apr 28, 2022

Betta Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to CN¥117

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.92 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.033 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.36 (vs CN¥0.33 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.50 (vs CN¥0.58 in FY 2019)

New 90-day low: CN¥95.46

Investor sentiment deteriorated over the past week

Betta Pharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

Analysts update estimates

Price target raised to CN¥97.57

New 90-day high: CN¥120

Market pulls back on stock over the past week

New 90-day low: CN¥99.80